1. Home
  2. UCAR vs CYCN Comparison

UCAR vs CYCN Comparison

Compare UCAR & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.45

Market Cap

9.2M

ML Signal

HOLD

Logo Cyclerion Therapeutics Inc.

CYCN

Cyclerion Therapeutics Inc.

HOLD

Current Price

$1.32

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCAR
CYCN
Founded
2013
2018
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
7.6M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
UCAR
CYCN
Price
$1.45
$1.32
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
14.4K
43.3K
Earning Date
10-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,816,075.00
$2,855,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
57.22
1371.65
52 Week Low
$1.43
$1.16
52 Week High
$9.43
$6.25

Technical Indicators

Market Signals
Indicator
UCAR
CYCN
Relative Strength Index (RSI) 24.03 39.10
Support Level $1.57 $1.16
Resistance Level $1.80 $1.51
Average True Range (ATR) 0.16 0.10
MACD -0.01 -0.02
Stochastic Oscillator 8.51 32.35

Price Performance

Historical Comparison
UCAR
CYCN

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Share on Social Networks: